Forward Pharma (FWP) Reports Q4 Loss of $1.01/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Leerink Partners Sees Forward Pharma (FWP) Shares Inflecting on Upcoming Patent Interference Decision
March 26, 2015 7:57 AM EDTLeerink Partners analyst Jason Gerberry reiterated an Outperform rating and $40 price target on Forward Pharma (NASDAQ: FWP), saying the shares to inflect on upcoming patent interference decision.
Gerberry commented, "We caught up with Joel Sendek, FWP's CFO, post this morning's financial results. Key updates... More
